Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • Log out
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • Log out
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds

Table of Contents

March 1, 1981; Volume 22,Issue 3
  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z

  1. Lamki, N.

    1. You have access
      Nonvisualization of Hepatoma with Tc-99m Hepatobiliary Agent
      N. Lamki, B. Raval and M. Chamberlain
      Journal of Nuclear Medicine March 1, 1981, 22 (3) 293;
  2. Lee, W. N. Paul

    1. You have access
      Simultaneous Determination of Free Thyroxine and Capacity of Thyroxine-Binding Globulin
      Michael D. Harpen, W. N. Paul Lee, Jeffry A. Siegel and Moses A. Greenfield
      Journal of Nuclear Medicine March 1, 1981, 22 (3) 246-252;
  3. Levine, Alexandra M.

    1. You have access
      Radiographic and Radionuclide Imaging in Multiple Myeloma: The Role of Gallium Scintigraphy: Concise Communication
      Alan D. Waxman, Jan K. Siemsen, Alexandra M. Levine, Diane Holdorf, Richard Suzuki, Frederick R. Singer and Joseph Bateman
      Journal of Nuclear Medicine March 1, 1981, 22 (3) 232-236;
  4. Levy, Ronald

    1. You have access
      Re: False-Negative Gallbladder Scintigram in Acute Cholecystitis
      Michael Brachman, Ronald Levy, Doina Tanasescu, Lalitha Ramanna and Alan Waxman
      Journal of Nuclear Medicine March 1, 1981, 22 (3) 291-292;
  5. Lewellen, T. K.

    1. You have access
      A Low-Contrast Phantom for Daily Quality Control
      T. K. Lewellen and Michael M. Graham
      Journal of Nuclear Medicine March 1, 1981, 22 (3) 279-282;
  6. Lyons, Kenneth P.

    1. You have access
      Imaging of Experimental Myocardial Infarction with Technetium-99m 2,3-Dimercaptosuccinic Acid
      Ronald P. Karlsberg, Norah Milne, Kenneth P. Lyons and Wilbert S. Aronow
      Journal of Nuclear Medicine March 1, 1981, 22 (3) 253-257;
Back to top
PreviousNext

In this issue

Journal of Nuclear Medicine
Vol. 22, Issue 3
March 1, 1981
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Advertising (PDF)
  • Back Matter (PDF)
  • Ed Board (PDF)
  • Front Matter (PDF)
Sign up for alerts
  • Most Cited
  • Most Read
Loading
  • MIRD Pamphlet No. 28, Part 1: MIRDcalc—A Software Tool for Medical Internal Radiation Dosimetry
  • Absorbed Dose–Response Relationship in Patients with Gastroenteropancreatic Neuroendocrine Tumors Treated with [177Lu]Lu-DOTATATE: One Step Closer to Personalized Medicine
  • Prediction of 177Lu-DOTATATE PRRT Outcome Using Multimodality Imaging in Patients with Gastroenteropancreatic Neuroendocrine Tumors: Results from a Prospective Phase II LUMEN Study
  • Renal and Multiorgan Safety of 177Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer in the VISION Dosimetry Substudy
  • High-Temporal-Resolution Lung Kinetic Modeling Using Total-Body Dynamic PET with Time-Delay and Dispersion Corrections
More...
SNMMI

© 2025 SNMMI

Powered by HighWire